Impact of mast cells on multiple sclerosis: Inhibitory effect of natalizumab

International Journal of Immunopathology and Pharmacology

Volumn 27, Issue 3, 2014, Pages 331-335

  Kritas, S K ^a   Saggini, A ^b   Cerulli, G ^c   Caraffa, A ^d   Antinolfi, P ^d   Pantalone, A ^e   Rosati, M ^f   Tei, M ^c   Speziali, A ^c   Saggini, R ^e   Frydas, A ^g   Conti, P ^e  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c Nicola's Foundation   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

^e UNIVERSITY OF CHIETI   (Italy)

^f Pescara Hospital   (Italy)

^g ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Mast cells; Multiple sclerosis; Natalizumab

Indexed keywords

CYTOKINE RECEPTOR; IMMUNOGLOBULIN E RECEPTOR; NATALIZUMAB; ALPHA4 INTEGRIN; MONOCLONAL ANTIBODY;

ALLERGIC REACTION; ASTROCYTE; AUTOIMMUNE DISEASE; BLOOD BRAIN BARRIER; CELL MATURATION; CROSS LINKING; DEGRANULATION; DEMYELINATION; HOST; HUMAN; MAST CELL; MULTIPLE SCLEROSIS; MYELIN SHEATH; NERVE CELL; PATHOGENESIS; PROTEIN DEGRADATION; RECURRENCE RISK; REVIEW; IMMUNOLOGY; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; INTEGRIN ALPHA4; MAST CELLS; MULTIPLE SCLEROSIS;

EID: 84908396110     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201402700303     Document Type: Review

References (31)

1. Korn T, Reddy J, Gao W, et al. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat Med 2007; 13(4):423-31.
2. Hafler DA, Weiner HL. T cells in multiple sclerosis and inflammatory central nervous system diseases. Immunol Rev 1987; 100:307-32.
3. Zhu J, Paul WE. Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev 2010; 238(1):247-62.
4. Sharief MK. Cytokines in multiple sclerosis: pro-inflammation or pro-remyelination? Mult Scler 1998; 4(3): 169-73.
5. Biddison WE, Cruikshank WW, Center DM, Pel- frey CM, Taub DD, Turner RV. CD8+ myelin pep- Tide-specific T cells can chemoattract CD4+ myelin peptide-speciflc T cells: importance of IFN-inducible protein 10. J Immunol 1998; 160(1):444-8.
6. Dimisianos N, Rodi M, Kalavrizioti D, Georgiou V, Papathanasopoulos P, Mouzaki A. cytokines as bio- markers of treatment response to IFN β in relapsing- remitting multiple sclerosis. Mult Scler Int 2014; 2014:436764.
7. Theoharides TC, Kempuraj D, Iliopoulou BP. Mast cells, T cells, and inhibition by luteolin: implications for the pathogenesis and treatment of multiple sclerosis. Adv Exp Med Biol 2007; 601:423-30.
8. Huang YM, Xiao BG, Ozenci V, Kouwenhoven M, Teleshova N, Fredrikson S, Link H. Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines. J Neuroimmunol 1999; 99(1):82-90.
9. Link H. The cytokine storm in multiple sclerosis. Mult Scler 1998; 4(1): 12-5.
10. Minami M. Cytokines and chemokines: mediators for intercellular communicatiop in the brain. Yakugaku Zasshi 2001; 121(12):875-85.
11. Kritas SK, Saggini A, Cerulli G, et al. Neuropeptide NGF mediates neuro-immune response and inflammation through, mast cell activation. J Biol Regul Homeost Agents 2014; 28(2):177-81.
12. Lassmann H. Neuropathology in multiple sclerosis: new concepts. Mult Scler 1998; 4(3):93-8.
13. Carrieri PB, Provitera V, De Rosa T, Tartaglia G, Gorga F, Perrella O. Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: A correlation with clinical activity. Immunopharmacol Immunotoxicol 1998; 20(3):373- 82.
14. Correale J. The role of microglial activation in disease progression. Mult Scler 2014; 20(10): 1288-95.
15. S.K. Kritas, A. Saggini, G. Cerulli, et al. Asthma and mast cell biology. Eur J Inflamm 2013; 12:261-265.
16. Kritas SK, Saggini A, Varvara G, et al. Mast cell involvement in rheumatoid arthritis. J Biol Regul Homeost Agents 2013; 27(3):655-60.
17. Kritas SK, Saggini A, Varvara G et al. Mast cell involvement in rheumatoid arthritis. J Biol Regul Homeost Agents 2013; 27(3):655-60.
18. S.K. Kritas, A. Caraffa, P. Antinolfi, et al. IgE generation and mast cell activation. Eur J Inflamm 2014; 12:21-25.
19. Karamitopoulou E, Shoni M, Theoharides TC. Increased number of non-degranulated mast cells in pancreatic ductal adenocarcinoma but not in acute pancreatitis. Int J Immunopathol Pharmacol 2014; 27(2):213-20.
20. Kritas SK, Saggini A, Cerulli G, et al. Corticotropin- releasing hormone, microglia and mental disorders. Int J Immunopathol Pharmacol 2014; 27(2): 163-7.
21. Theoharides TC, Kempuraj D, Iliopoulou BP. Mast cells, T cells, and inhibition by luteolin: implications for the pathogenesis and treatment of multiple sclerosis. Adv Exp Med Biol 2007; 601:423-30.
22. Ransohoff RM, Brown MA. Innate immunity in the central nervous system. J Clin Invest 2012; 122(4): 1164-71.
23. Secor VH, Secor WE, Gutekunst CA, Brown MA. Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J Exp Med 2000; 191(5):813-22.
24. Kritas SK, Saggini A, Varvara G, et al. Luteolin inhibits mast cell-mediated allergic inflammation. J Biol Regul Homeost Agents 2013; 27(4):955-9.
25. Van den Broek HH, Damoiseaux JG, De Baets MH, Hupperts RM. The influence of sex hormones oncytokines in multiple sclerosis and experimental autoimmune encephalomyelitis: A review. Mult Scler 2001 11(3):349-59.
26. Bennett JL, Stuve O. Update on inflammation, neu- rodegeneration, and immunoregulation in multiple sclerosis: Therapeutic implications. Clin Neurophar- macol 2009; 32(3): 121-32.
27. M. Gironi, B. Borgiani, C. Cursano,et al. The peripheral network between oxidative stress and inflammation in multiple sclerosis. Eur J Inflamm 2014; 12:351-63.
28. Totaro R, Lugaresi A, Bellantonio P, et al. Natalizum- Ab treatment in multiple sclerosis patients: A multi- center experience in clinical practice in Italy. Int J Immunopathol Pharmacol 2014; 27(2): 147-54.
29. Barbaud A, Granel F, Waton J, Poreaux C. How to manage hypersensitivity reactions to biological agents? Eur J Dermatol 2011; 21 (5):667-74.
30. Prat A, Biernacki K, Wosik K, Antel JP. Glial cell influence on the human blood-brain barrier. Glia 2001; 36(2): 145-55.
31. Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. Eur Neurol 2014; 72(3-4): 132-41.